Affordable Access

deepdyve-link
Publisher Website

[Management of aflibercept in routine clinical practice].

Authors
  • Cabrera López, F1
  • 1 Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria, España; Profesor Asociado, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España; Sociedad Española de la Retina y Vítreo, Instituto de Salud Carlos III, Madrid, España; Red Temática de Investigación Cooperativa OFTARED, Instituto de Salud Carlos III, Madrid, España. Electronic address: [email protected]
Type
Published Article
Journal
Archivos de la Sociedad Espanola de Oftalmologia
Publication Date
March 2015
Volume
90 Suppl 1
Pages
29–34
Identifiers
DOI: 10.1016/S0365-6691(15)30007-1
PMID: 25925049
Source
Medline
Keywords
License
Unknown

Abstract

Aflibercept is a new anti-vegf drug that, unlike ranibizumab and bevacizumab blocks both vegf-A and placental growth factor. Moreover, it binds with much greater strength and affinity to human VEGF-A165 than other endogenous vegf receptors, conferring it with a more extended effect and allowing a lower frequency of intravitreal injections. This facilitates the adoption of fixed treatment regimens other than monthly or individual regimens such as "treat and extend". Aflibercept is indicated for the treatment of neovascular (exudative) age-related macular degeneration (ARMD), visual alteration due to macular edema secondary to central retinal vein occlusion (CRVO) and visual alteration due to diabetic macular edema (DME). The present article reviews the management of aflibercept in routine clinical practice, based on the specifications of its new core data sheet, which includes all the therapeutic indications in which its use has been approved and evaluating the distinct alternatives and treatment regimens after the initial loading doses.

Report this publication

Statistics

Seen <100 times